Review article: Emerging insights into the epidemiology, pathophysiology, diagnostic and therapeutic aspects of eosinophilic oesophagitis and other eosinophilic gastrointestinal diseases
Alimentary Pharmacology & Therapeutics · 2024-02 · 59 (3) · 322-340
DOI: 10.1111/apt.17845 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 22.12.2023. Verfasst von Eric E Low und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, University of California San Diego, San Diego, California, USA. Hauptthemen laut MEDLINE: Gastritis, Eosinophilic Esophagitis, Enteritis. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 186 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Background
Eosinophilic gastrointestinal diseases (EGIDs) are chronic, immune‐mediated disorders characterised clinically by gastrointestinal symptoms and histologically by a pathologic increase in eosinophil‐predominant inflammation in the gastrointestinal tract, in the absence of secondary causes of eosinophilia.
Aims
To highlight emerging insights and research efforts into the epidemiology, pathophysiology, diagnostic and therapeutic aspects of eosinophilic oesophagitis (EoE) and non‐EoE EGIDs, and discuss key remaining knowledge gaps.
Methods
We selected and reviewed original research, retrospective studies, case series, randomised controlled trials, and meta‐analyses.
Results
Standardised nomenclature classifies EGIDs as EoE, eosinophilic gastritis (EoG), eosinophilic enteritis (EoN), and eosinophilic colitis (EoC). Incidence and prevalence of EoE are rising, emphasising the need to better understand how environmental risk factors and genetic features interact. Advances in understanding EoE pathophysiology have led to clinical trials of targeted therapy and the approval (in the United States) of dupilumab for EoE. Several therapies that are under investigation hope to satisfy both histologic and clinical targets. For non‐EoE EGIDs, efforts are focused on better defining clinical and histopathologic disease determinants and natural history, as well as establishing new therapies.
Conclusions
Unmet needs for research are dramatically different for EoE and non‐EoE EGIDs. In EoE, non‐invasive diagnostic tests, clinicopathologic models that determine the risk of disease progression and therapeutic failure, and novel biologic therapies are emerging. In contrast, in non‐EoE EGIDs, epidemiologic trends, diagnostic histopathologic thresholds, and natural history models are still developing for these more rare disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, University of California San Diego, San Diego, California, USA.
- Center for Esophageal Diseases and Swallowing, Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
ORCID-Profile: Eric E Low, Evan S Dellon
Förderung
- NIDDK NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Low, E. E., & Dellon, E. S. (2024). Review article: Emerging insights into the epidemiology, pathophysiology, diagnostic and therapeutic aspects of eosinophilic oesophagitis and other eosinophilic gastrointestinal diseases. Alimentary Pharmacology & Therapeutics, 59(3), 322-340. https://doi.org/10.1111/apt.17845
Vancouver
Low EE, Dellon ES. Review article: Emerging insights into the epidemiology, pathophysiology, diagnostic and therapeutic aspects of eosinophilic oesophagitis and other eosinophilic gastrointestinal diseases. Alimentary Pharmacology & Therapeutics. 2024;59(3):322-340. doi:10.1111/apt.17845
BibTeX
@article{Low2024,
author = {Low, Eric E and Dellon, Evan S},
title = {Review article: Emerging insights into the epidemiology, pathophysiology, diagnostic and therapeutic aspects of eosinophilic oesophagitis and other eosinophilic gastrointestinal diseases},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
volume = {59},
number = {3},
pages = {322--340},
doi = {10.1111/apt.17845}
}
EUVIMED